×
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
NASDAQ:GOVX

GeoVax Labs Stock Forecast, Price & News

$1.26
-0.05 (-3.82%)
(As of 06/24/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.22
$1.34
50-Day Range
$0.62
$2.32
52-Week Range
$0.55
$7.50
Volume
1.02 million shs
Average Volume
5.23 million shs
Market Capitalization
$11.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00
30 days | 90 days | 365 days | Advanced Chart

Receive GOVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GeoVax Labs and its competitors with MarketBeat's FREE daily newsletter.

GOVX Stock Forecast (MarketRank)

Overall MarketRank

2.03 out of 5 stars

Medical Sector

552nd out of 1,418 stocks

Pharmaceutical Preparations Industry

245th out of 679 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
GeoVax Labs logo

About GeoVax Labs (NASDAQ:GOVX)

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.

GOVX Stock News Headlines

GeoVax Labs falls 27% on direct offering
052022 B Small Public Co Reynolds CFO
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GOVX
Employees
11
Year Founded
N/A

Company Calendar

Last Earnings
4/27/2022
Today
6/24/2022
Next Earnings (Estimated)
8/10/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+376.2%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
1 Analysts

Profitability

Net Income
$-18.57 million
Net Margins
-5,443.98%
Pretax Margin
-5,443.98%

Debt

Sales & Book Value

Annual Sales
$390 thousand
Book Value
$0.68 per share

Miscellaneous

Free Float
8,948,000
Market Cap
$11.91 million
Optionable
Not Optionable
Beta
1.78














GeoVax Labs Frequently Asked Questions

Should I buy or sell GeoVax Labs stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GeoVax Labs in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GeoVax Labs stock.
View analyst ratings for GeoVax Labs
or view top-rated stocks.

What is GeoVax Labs' stock price forecast for 2022?

1 Wall Street research analysts have issued 12 month price objectives for GeoVax Labs' stock. Their GOVX stock forecasts range from $6.00 to $6.00. On average, they predict GeoVax Labs' share price to reach $6.00 in the next year. This suggests a possible upside of 376.2% from the stock's current price.
View analysts' price targets for GeoVax Labs
or view top-rated stocks among Wall Street analysts.

How has GeoVax Labs' stock price performed in 2022?

GeoVax Labs' stock was trading at $3.62 at the start of the year. Since then, GOVX stock has decreased by 65.2% and is now trading at $1.26.
View the best growth stocks for 2022 here
.

Are investors shorting GeoVax Labs?

GeoVax Labs saw a increase in short interest in May. As of May 31st, there was short interest totaling 3,210,000 shares, an increase of 4,698.2% from the May 15th total of 66,900 shares. Based on an average daily trading volume, of 9,200,000 shares, the short-interest ratio is currently 0.3 days.
View GeoVax Labs' Short Interest
.

When is GeoVax Labs' next earnings date?

GeoVax Labs is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022.
View our earnings forecast for GeoVax Labs
.

How were GeoVax Labs' earnings last quarter?

GeoVax Labs, Inc. (NASDAQ:GOVX) released its earnings results on Wednesday, April, 27th. The company reported ($0.34) earnings per share for the quarter. The business earned $0.08 million during the quarter. GeoVax Labs had a negative trailing twelve-month return on equity of 146.19% and a negative net margin of 5,443.98%.
View GeoVax Labs' earnings history
.

Who are GeoVax Labs' key executives?

GeoVax Labs' management team includes the following people:
  • Mr. David Alan Dodd, Chairman, Pres & CEO (Age 72, Pay $381.5k)
  • Mr. Mark W. Reynolds CPA, CPA, CFO & Corp. Sec. (Age 60, Pay $339.99k)
  • Dr. Mark J. Newman Ph.D., Chief Scientific Officer (Age 67, Pay $175k)
  • Dr. Harriet Latham Robinson, Founder, Chief Scientific Officer Emeritus & Member of Scientific Advisory Board (Age 84)
  • Dr. Kelly T. McKee Jr., M.D., M.P.H., Chief Medical Officer (Age 72)
  • Jeffrey Welch, Head of Process Devel. & Manufacturing Operations

What is GeoVax Labs' stock symbol?

GeoVax Labs trades on the NASDAQ under the ticker symbol "GOVX."

Who are GeoVax Labs' major shareholders?

GeoVax Labs' stock is owned by a number of institutional and retail investors. Top institutional investors include Virtu Financial LLC (0.53%). Company insiders that own GeoVax Labs stock include David A Dodd, Kelly T Jr Mckee, Mark Reynolds and Randal D Chase.
View institutional ownership trends for GeoVax Labs
.

Which institutional investors are buying GeoVax Labs stock?

GOVX stock was acquired by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have bought GeoVax Labs stock in the last two years include David A Dodd, Kelly T Jr Mckee, Mark Reynolds, and Randal D Chase.
View insider buying and selling activity for GeoVax Labs
or or view top insider-buying stocks.

How do I buy shares of GeoVax Labs?

Shares of GOVX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is GeoVax Labs' stock price today?

One share of GOVX stock can currently be purchased for approximately $1.26.

How much money does GeoVax Labs make?

GeoVax Labs (NASDAQ:GOVX) has a market capitalization of $11.91 million and generates $390 thousand in revenue each year. The company earns $-18.57 million in net income (profit) each year or ($3.10) on an earnings per share basis.

How many employees does GeoVax Labs have?

GeoVax Labs employs 11 workers across the globe.

How can I contact GeoVax Labs?

GeoVax Labs' mailing address is 1900 LAKE PARK DRIVE SUITE 380, SMYRNA GA, 30080. The official website for GeoVax Labs is www.geovax.com. The company can be reached via phone at (678) 384-7220, via email at [email protected], or via fax at 678-384-7281.

This page (NASDAQ:GOVX) was last updated on 6/24/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.